Focused On-demand Library for Dehydrogenase/reductase SDR family member 7B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6IAN0

UPID:

DRS7B_HUMAN

Alternative names:

Short-chain dehydrogenase/reductase family 32C member 1

Alternative UPACC:

Q6IAN0; B5MEF4; Q6UX59; Q9BTF9; Q9UFM6; Q9Y3A1

Background:

Dehydrogenase/reductase SDR family member 7B, also known as Short-chain dehydrogenase/reductase family 32C member 1, is classified as a putative oxidoreductase. This protein plays a crucial role in the metabolic processes, facilitating the oxidation and reduction reactions that are essential for cellular energy production and detoxification.

Therapeutic significance:

Understanding the role of Dehydrogenase/reductase SDR family member 7B could open doors to potential therapeutic strategies. Its involvement in key metabolic pathways highlights its potential as a target for drug discovery, aiming to modulate metabolic disorders and diseases linked to oxidative stress.